Lysine succinylation, the metabolic bridge between cancer and immunity

Rui Shen; Hongyun Ruan; Shuye Lin; Bin Liu; Hang Song; Lu Li; Teng Ma

doi:10.1016/j.gendis.2022.10.028

Lysine succinylation, the metabolic bridge between cancer and immunity

Genes Dis. 2022 Dec 1;10(6):2470-2478. doi: 10.1016/j.gendis.2022.10.028. eCollection 2023 Nov.

Authors

Rui Shen¹, Hongyun Ruan², Shuye Lin², Bin Liu², Hang Song^{1

3}, Lu Li^{1

3}, Teng Ma²

Affiliations

¹ School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, Anhui 230012, China.
² Cancer Research Centre, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
³ Department of Biochemistry and Molecular Biology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, Anhui 230012, China.

Abstract

Lysine succinylation is a naturally occurring post-translational modification (PTM) that regulates the stability and function of proteins. It can be regulated by enzymes such as SIRT5 and SIRT7. Recently, the effect and significance of lysine succinylation in cancer and its implication in immunity have been extensively explored. Lysine succinylation is involved in the malignant phenotype of cancer cells. Abnormal regulation of lysine succinylation occurs in different cancers, and inhibitors targeting lysine succinylation regulatory enzymes can be used as potential anti-cancer strategies. Therefore, this review focused on the target protein lysine succinylation and its functions in cancer and immunity, in order to provide a reference for finding more potential clinical cancer targets in the future.

Keywords: Immunity; Mitochondria; SIRT5; Succinyl-CoA; Succinylation.

Publication types

Review